TY - JOUR
T1 - Reinventing bone marrow transplantation
T2 - Reducing toxicity using nonmyeloablative, preparative regimens and induction of graft-versus-malignancy
AU - Champlin, Richard
AU - Khouri, Issa
AU - Kornblau, Steven
AU - Molldrem, Jeffrey
AU - Giralt, Sergio
N1 - Copyright:
Copyright 2007 Elsevier B.V., All rights reserved.
PY - 1999
Y1 - 1999
N2 - Bone marrow transplantation was initially developed as a means to deliver supralethal doses of chemotherapy and radiation for treatment of malignancies. Myelosuppression is the dose-limiting toxicity for many chemotherapy drugs and whole-body radiation. Many malignancies exhibit a steep dose-response relationship to chemotherapy or radiotherapy. Bone marrow transplantation allows escalation of doses beyond those levels which produce severe bone marrow toxicity. Doses of many agents, particularly alkylating agents and whole body radiation, can be increased three- to fivefold above their conventional maximally tolerated dose. Marrow transplantation was considered a supportive care modality to restore hematopoiesis. It has become clear, however, that the high dose therapy does not eradicate the malignancy in many patients, and that the therapeutic benefit of allogeneic marrow transplantation is largely related to an associated immune-mediated graft-versus-malignancy effect.
AB - Bone marrow transplantation was initially developed as a means to deliver supralethal doses of chemotherapy and radiation for treatment of malignancies. Myelosuppression is the dose-limiting toxicity for many chemotherapy drugs and whole-body radiation. Many malignancies exhibit a steep dose-response relationship to chemotherapy or radiotherapy. Bone marrow transplantation allows escalation of doses beyond those levels which produce severe bone marrow toxicity. Doses of many agents, particularly alkylating agents and whole body radiation, can be increased three- to fivefold above their conventional maximally tolerated dose. Marrow transplantation was considered a supportive care modality to restore hematopoiesis. It has become clear, however, that the high dose therapy does not eradicate the malignancy in many patients, and that the therapeutic benefit of allogeneic marrow transplantation is largely related to an associated immune-mediated graft-versus-malignancy effect.
UR - http://www.scopus.com/inward/record.url?scp=0032992942&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032992942&partnerID=8YFLogxK
U2 - 10.1097/00001622-199903000-00003
DO - 10.1097/00001622-199903000-00003
M3 - Review article
C2 - 10188072
AN - SCOPUS:0032992942
SN - 1040-8746
VL - 11
SP - 87
EP - 95
JO - Current opinion in oncology
JF - Current opinion in oncology
IS - 2
ER -